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Background: Foetal and neonatal alloimmune thrombocytopenia (FNAIT) is 
estimated to occur at an incidence of 1:1-2000 live borns, while maternal 
immunisation against HLA class I is a common finding during pregnancy and after 
delivery. Whether anti-HLA antibodies can cause FNAIT in some cases is debateable. 
Aim: This study aims to give a background to FNAIT, and to describe cases of 
suspected or anticipated FNAIT referred to the thrombocyte and leukocyte laboratory 
at Karolinska University Hospital, with a focus on cases that could be due to anti-
HLA class I antibodies. In an experimental part, anti-HLA class I antibody 
specificities in selected cases were analysed and the expression of HLA class I 
antigens on adult and umbilical cord blood platelets was determined. Results: Out of 
260 patients referred from January 2007 until March 2012, alloantibodies were 
detected in 43%, and anti-HLA class I antibodies were most common. 35 patients 
were diagnosed with FNAIT with HPA incompatibilities between the parents and 
detectable antibodies. Sera from 23 anti-HLA class I immunised mothers were 
analysed further, and most of them had antibodies reactive with several specificities. 
The most common specificities were of the HLA-B type, against rare alleles. Flow 
cytometry analysis of HLA-A,B,C and HLA-B,C on platelets indicated that platelets 
from neonates had a higher HLA-A expression and lower HLA-BC expression. 
Conclusion: FNAIT is rare, and is probably even more rarely caused by HLA class I 
immunisation, although it remains a possibility. Maternal anti-HLA class I antibodies 
have been shown to be associated with complications related to pregnancy, and it is 
not clear how the presence of these antibodies affects the foetus. In cases of suspected 
HLA alloimmunisation, most of the mothers had broadly reacting antibodies. The 
expression of HLA class I on platelets seems to be different in adult and umbilical 
cord blood.  
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Aims	  and	  outline	  
The aim of this study was to give a background to foetal and neonatal alloimmune 
thrombocytopenia (FNAIT), and to describe cases of suspected or anticipated FNAIT 
referred to the thrombocyte and leukocyte laboratory (TRoLL) at Karolinska 
University Hospital, with a focus on cases which could be due to anti-HLA class I 
antibodies. In an experimental part, the anti-HLA class I antibody specificities in 
selected cases were analysed, and the expression of HLA class I antigens on adult and 
umbilical cord blood platelets was determined by flow cytometry.  
 
Introduction	  
An	  overview	  of	  foetal	  and	  neonatal	  alloimmune	  thrombocytopenia	  	  
Foetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition where the 
alloantigens on the platelets of the foetus are not compatible with those of the mother. 
This incompatibility may already in the first pregnancy cause an immunisation of the 
mother, and a subsequent transfer of IgG antibodies across the placenta targeted 
towards the foetus' platelets. The presence of antibodies in foetal circulation may in 
turn lead to the destruction of platelets and possibly thrombocytopenia in the foetus or 
newborn. A low platelet count puts the foetus at risk of bleeding complications, in 
utero or after delivery. The incidence of FNAIT is reported to be about 1 per 1-2000 
live born neonates, and severe FNAIT occurs in about 60 per 100 000 pregnancies [2].  
The complications range from no symptoms, to skin bleedings, to intracranial 
haemorrhage (ICH). ICH is the major concern of this disease, as it is associated with 
severe neurological complications and death. About 10-15% of affected neonates 
suffer from intracranial haemorrhage [3]. There is no prophylactic treatment of 
FNAIT, as opposed to haemolytic disease of the foetus and newborn (HDFN), 
although administration of platelet antibodies in mice has been proven to prevent poor 
pregnancy outcome in FNAIT [4]. In 85% of cases in the Caucasian population the 
antigen is human platelet antigen 1a, followed by HPA-5b [5]. About 2% of the 
Caucasian population are HPA-1a negative, out of which 10% become immunised [2, 
6]. The foetus has been shown to express HPA-1a on platelets as early as at 16 weeks 
of gestation [7], but the antigen is probably available to the mother's immune system 
	   4	  
earlier, since it has been shown to be expressed by syncytiotrophoblast cells in first 
trimester placentas[8]. As no country has implemented any screening-programme, 
today most cases are diagnosed after the birth of a thrombocytopenic child.  
 
Human	  leukocyte	  antigen	  (HLA)	  class	  I	  alloimmunisation	  in	  pregnancy	  
Mothers may also become immunised against paternal human leukocyte class I 
antigen during pregnancy, and it is estimated that 7-39% of mothers form anti-HLA 
class I alloantibodies [9]. Detection of anti-HLA class I alloantibodies together with 
anti-HPA alloantibodies is also a common finding in FNAIT-cases. There are a 
number of case reports where in suspected cases of FNAIT, only anti-HLA class I 
alloantibodies are detected. In many of these case reports alloimmunisation against 
rare platelet-specific antigens, like HPA-5b, HPA-3a and HPA-15b are not excluded 
[10-12]. It is also possible that some are missed because of delayed antibody detection 
or undetectable antibodies [9]. More recently there are reports where specific anti-
HLA class I alloantibodies are the likely cause of neonatal thrombocytopenia [13, 14]. 
However, FNAIT is rare, and anti-HLA class I alloantibodies during pregnancy are 
not, especially in multiparous women. When and why anti-HLA class I alloantibodies 
in some cases cause neonatal thrombocytopenia is not known. Alloimmune neonatal 
neutropenia (ANN) together with FNAIT is even more rare, but there are case reports 
with specific anti-HLA class I alloantibodies detected in the foetus alone [15], and 
together with neutrophil and platelets specific antibodies [16].  
 Boys seem to be at increased risk of adverse effects of maternal alloantibodies 
during pregnancy compared to girls: The level of anti-HPA-1a antibodies is 
associated with a reduced birth weight in boys [17], and anti-HLA class I antibodies 
are more frequent in women with a firstborn boy in cases of secondary recurrent 
miscarriage [18].  
 Thrombocytopenia in children that are small for gestational age (SGA) has 
been reported to be associated with anti-HLA class I antibodies [19]. In the study 
from 1991, the presence of anti-HLA class I antibodies in SGA infants was compared 
to that of a group of non-thrombocytopenic SGA infants and healthy full terms. The 
authors found that the incidence of anti-HLA antibodies in the thrombocytopenic 
SGA group was highest, and that in these children the leukocyte and lymphocyte 
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counts were lower in the first week of life compared to children of non-immunised 
mothers. 
Background	  
Thrombocytopenia	  in	  neonates	  
Thrombocytopenia is a low platelet count, defined as <150 x 109/L in adults and 
neonates born ≥ 22 weeks of gestation. The platelet count increases progressively and 
reaches this level by the second trimester [20-22]. The most common causes of 
thrombocytopenia in neonates in addition to FNAIT are autoimmune disorders 
(maternal ITP, lupus), infections (GBS, CMV), placental insufficiency (preeclampsia, 
chronic hypertension), asphyxia, genetic disorders (chromosomal, familial or 
metabolic), and medications (antibiotics, anticonvulsants). Usually cases of neonatal 
thrombocytopenia are mild to moderate[23]. FNAIT is the most common cause of 
severe early onset thrombocytopenia in otherwise healthy neonates, defined as a 
platelet count <50 x 109/L [24]. Thrombocytopenia occurs in 1 - 5 % of new-borns at 
birth, and severe thrombocytopenia (<50 x 109/L) occurs in 0.1 - 0.5%. However, this 
is a more common problem in the Neonatal Intensive Care Unit (NICU), where 22 - 
35% develop thrombocytopenia and a more considerable proportion is severe. 8% of 
preterm and 6% of all neonates in NICU have severe thrombocytopenia [25].   
Clinical	  signs	  of	  alloimmune	  thrombocytopenia	  
Thrombocytopenia caused by FNAIT will usually be severe and present at birth, or 
with platelet count nadir within 72 hours after delivery [23, 26]. The child will often 
be otherwise well, without an obvious explanation for the thrombocytopenia. ICH is 
highly indicative of FNAIT when the 1-min Apgar score is >5, the birth weight is 
>2,200 g, the ICH is in utero, the birth platelet count is <40 x 109, and/or bleeding 
symptoms are present [26]. A sibling with transient thrombocytopenia is a clinical 
criterion to suspect FNAIT [26] and a predictor of severe disease [27]. It is important 
to recognize cases of FNAIT, as it may be more severe in subsequent pregnancies and 
the recurrence rate of FNAIT among siblings is high [3]. 
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Predictors	  of	  severe	  FNAIT	  
Both obstetric history and laboratory findings are important tools to predict the 
severity of an anticipated case of FNAIT.  
 Children with older siblings suffering from antenatal ICH or severe 
thrombocytopenia (here defined as <20 x 109/L) have significantly lower platelet 
count compared with those who had a sibling with less severe ICH or 
thrombocytopenia [28]. A history of previous FNAIT as a predictor is shown to have 
a high specificity of 92%, but a low sensitivity of 13% [29].  Women without 
previous FNAIT may give birth to children with severe thrombocytopenia [29], and 
those who have previously given birth to a severely affected child can give birth to 
healthy children in subsequent pregnancies [30].  
A high aHPA-1a alloantibody level in the third trimester is associated with 
severe thrombocytopenia [31], and measuring the level of aHPA-1a alloantibodies 
during pregnancy has been shown by Killie et al to be a predictor of severe FNAIT 
with a high diagnostic sensitivity of 93% and diagnostic specificity of 63%, with a 
cut-off level of 3.0 IU/mL.  
 Most HPA-1a negative women who become immunised express the MHC 
class II allele HLA DRB3*0101 [30, 31]. In the same study by Killie et al, 90% of 
HPA-1a negative mothers who became immunised had the allele, and those who did 
not had a significantly lower aHPA-1a antibody level. The HLADQB1*0201 HLA 
class II allele has also been shown to be overrepresented amongst HPA-1a negative 
women that become immunised, and there is an overrepresentation of the 
HLADRB3*0101 allele in these HLADQB1*0201 positive women [32, 33]. The 
frequency of individuals testing positive for HLADQB1*0201 and HLADRB3*0101 
in the normal population is about 40% and less than 30%, respectively [32, 33]. The 
presence of the HLA DRB3*0101 phenotype does not predict alloimmunization 
(positive predictive value =35%), but the absence of it makes alloimmunization 
unlikely with a negative predictive value of 99.6% [31]. 
 A possible correlation between severe FNAIT and maternal ABO blood type 
has recently been shown. From the large screening study in Norway including 100 
448 pregnant women, immunised mothers with blood group O were shown to have a 
lower risk of having a child with severe FNAIT than women with group A (RR 0.43; 
95% CI 0.25-0.75) [34]. 
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Intracranial	  haemorrhage	  (ICH)	  in	  neonates	  
The incidence or prevalence of ICH is not known, and is probably underestimated as 
only some present with symptoms. The incidence varies in different studies probably 
due to differences in study populations, sensitivity and timing of diagnostic imaging 
used [35]. One study completed MR imaging evaluation in 88 full-term neonates at 
ages of 1 to 5 weeks. Out of 17 identified neonates with ICH, all were delivered 
vaginally, with a prevalence of asymptomatic ICH in 26% of vaginal births. ICH was 
associated with vaginal delivery, but not with prolonged duration of labour or with 
traumatic or assisted vaginal birth [36]. In a large retrospective study on nearly 600 
000 average weight infants (2500-4000g) born to nulliparous women, the incidence of 
symptomatic ICH varied according to mode of delivery (1 per 664 delivered with use 
of forceps, 1 per 860 vacuum extraction delivery, 1 of 907 delivered by CS during 
labour, 1 per 1900 delivered naturally and 1 per 2750 delivered by CS without 
labour), suggesting the common risk factor for haemorrhage as abnormal labour. A 
case-control study with 66 full-term infants with ICH showed that low Apgar scores 
(1-4) increased risk of ICH (OR 110), compared to a normal Apgar score (9-10), and 
respiratory distress was associated with ICH [37]. It is difficult to ascertain a direct 
causal relationship between perinatal asphyxia and ICH as there are suggested two 
sequences leading to ICH/IVH: Hypoxia and hypercapnia of the neonatal respiratory 
distress syndrome may cause a primary hyperperfusion with breakdown of 
microcirculation, and birth asphyxia may cause hypoperfusion with ischaemic damage 
to the microcirculation and haemorrhage following the restoration of normal flow 
[38]. Also, children with ICH may present with respiratory distress [39]. 
 Thrombocytopenia has been shown to be the most important factor related to 
the occurrence of ICH and greater radiological severity [37]. The risk increases with 
more severe thrombocytopenia, and most cases happen with platelet counts of less 
than 30 x 109/L [35]. 
The different types of ICH are defined after location and classified on severity. 
Infratentorial, subdural haemorrhage has been reported to be the most common in 
asymptomatic newborns [36], and subarachnoid among symptomatic newborns [40]. 
Intraventricular haemorrhage (IVH) is a major complication in premature infants, and 
is ascribed to the inherent fragility of the developing brain's vasculature (most IVH 
initiates in the germinal matrix), disturbance in cerebral blood flow and platelet and 
coagulation disorders, which contributes to haemostatic failure [41]. Intraparenchymal 
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haemorrhage is reported to be rare in full-term newborns, and no cause is identified in 
most term newborns with spontaneous bleedings [42], but it has been shown to be 
strongly associated with a low platelet count (<50 x 109/L) [37].  
In general, superficial haemorrhage is common in birth trauma or with 
instrument-assisted delivery, and deep haemorrhage is common in non-traumatic 
haemorrhage[35].  
 Clinical features of ICH in newborns differ from those of older children and 
adults (headache, focal neurological signs), and they may manifest with neonatal 
seizures, generalized hypotonia, decreased level of consciousness, respiratory distress, 
apnea with tachycardia (seizure activity) or bradycardia (increased intracranial 
pressure)[35].   
Prematurity	  and	  thrombocytopenia	  
Thrombocytopenia is a common finding in premature infants, but the mechanism for 
this is not clear. In a cohort study, more than 70% of 284 extremely low birth weight 
neonates were observed to be thrombocytopenic, a rate more than twice that reported 
in the general NICU population, 52% were diagnosed (48% had no explanation) with 
the most common causes as being small for gestational age or delivered to 
hypertensive mother. Thrombocytopenia was most common in those of lowest weight, 
the majority of cases were identified in the first week of life, and the mortality rate 
twice as high in platelet transfused patients [43]. In a large population study including 
over 47,000 patients with the objective to create platelet range values for neonates 
[44], the postnatal platelet counts increased with advancing gestational age and infants 
born between 22 and 35 gestational week (GW) had significantly lower platelet 
counts than late pre-term or term neonates. In the same study, neonates of all 
gestational ages had a lower 5th percentile value than the adult standard value of 150 
x 109/L. The report also found that the platelet counts increased during the neonatal 
period, with two peaks at 2-3 weeks and at 6-7 weeks. The first peak is suggested as 
the result of an increased thrombopoeitin (TPO) concentration, while the second can 
be attributed to a number of different causes. The platelet count of the most premature 
infants (those born in 22-27 GW) did not increase until they reached a corrected 
gestational age of 29 weeks, and the mean value remained below the mean platelet 
counts of near-term or term infants. Those born at 29 weeks increased steadily until 
reaching an age of 36 weeks, to levels similar to infants born to late preterm and term. 
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Excluding the top and lower 5th percentile, the lowest limit was 104x109/L and 
123x109/L in infants born <32 weeks and >32 weeks gestation, respectively. 
However, the study did not exclude ill infants, and so the values cannot be regarded as 
"normal values", but rather epidemiologic "reference ranges" for the NICU 
population[45]. 
Human	  platelet	  antigens	  
Human platelet antigens as reviewed by Santoso 2003[46] are described as type I and 
type II alloantigens. Type I alloantigens are shared with other blood cells and tissues, 
such as glycoconjugates of the ABH system and the HLA class I molecule. Type II 
alloantigens are more specific to platelets and conventionally called platelet specific 
alloantigens (HPA). These normally play the major role in FNAIT. The different HPA 
antigens are numbered chronologically after date of description. The high-frequency 
allele of a system is named "a" and the low frequency "b". The alloantigens are 
located on six different platelet membrane glycoproteins or integrins, GPIa, GPIbα, 
GPIbβ, GPIIb, GPIIIa and GPI-linked CD109. The different alloantigens are mostly 
determined by single amino acid substitutions induced by point mutations of the 
respective gene. 
 Of the "platelet specific" antigens, many of these have been found on other 
cells and tissues, as members of molecules involved in cell-matrix or cell-cell 
interactions (cell adhesion receptors or integrins). See table 1 for examples and 
references. 
 The presence of these alloantigens on other cells than platelets is of 
importance in relation to when the immunization of the mother takes place. In 
haemolytic disease of the foetus and newborn (HDFN) the RhD antigen is only 
present on red blood cells of the foetus, and immunization most often occur after 
delivery or other foetal-maternal haemorrhaging (FMH), when foetal blood is mixed 
with maternal blood. If the HPA-1a antigen is available for the mother's immune 
system before delivery or earlier in the pregnancy, one could anticipate seeing 
mothers being immunised in their first pregnancy. This is the case in less than 25% of 
FNAIT cases[29, 31], and may suggest that the HPA-1a antigens are more 
immunogenic compared to the RhD antigen during pregnancy (as perhaps a smaller 
FMH may lead to HPA immunization), or that there is a different source of the HPA-
1a alloantigen other than platelets for these cases. Syncytiotrophoblast debris known 
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to enter the maternal circulation during pregnancy[47], have been a suggested source. 
Syncytiotrophoblasts may express HPA-1a, but lack HLA class I A and B[48].  
 
 
Table	  1	  The	  most	  common	  platelet	  antigens	  in	  FNAIT.	  Modified	  after	  Santoso	  (2003).	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The	  HLA	  system	  
As presented by Parham [55], the major histocompatibility complex (MHC) are 
proteins involved in antigen processing and presentation, and are so called because of 
their ability to cause T-cells to reject tissues transplanted from unrelated donors to 
recipients. In humans MHC is called the human leukocyte antigen (HLA) complex 
because antibodies used to detect human MHC react with leukocytes, but not with red 
blood cells, which lack HLA.  
 The diversity of MHC is due to the way it is inherited, as the encoding genes 
are stable and do not undergo developmental or somatic processes of structural 
change. There are multiple similar genes encoding the MHC class I heavy chains, 
MHC class II α and MHC class II β chains, constituting different gene families. 
Furthermore, there are multiple alternative forms of the same genes (genetic 
polymorphism). Products of the different molecules in a MHC class I or II family are 
called isotypes, and the product of a given form of a gene (allele) is called allotype. 
An isoform denotes a particular MHC protein. 
 There are six isotypes of HLA class I: HLA-A, HLA-B, HLA-C, HLA-E, 
HLA-F and HLA-G, and five HLA class II isotypes: HLA-DM, HLA-DO, HLA-DP, 
HLA-DQ and HLA-DR. The different isotypes of HLA are polymorphic to a varying 
extent, but overall there is greater diversity in HLA class I than in HLA class II 
molecules.   
  
 
Figure	  1	  Structure	  of	  HLA	  Class	  I	  and	  Class	  II	  molecules[1].	  Beta2-­‐microglobulin	  is	  the	  light	  chain	  of	  the	  
class	  I	  molecule.	  The	  α	  chain	  of	  the	  class	  I	  molecule	  has	  two	  peptide-­‐binding	  domains	  (α1	  and	  α2),	  an	  
immunoglobulin-­‐like	  domain	  (α3),	  the	  transmembrane	  region	  (TM),	  and	  the	  cytoplasmic	  tail.	  Each	  of	  the	  
class	  II	  α	  and	  ß	  chains	  has	  four	  domains:	  the	  peptide-­‐binding	  domain	  (α1	  or	  ß1),	  the	  immunoglobulin-­‐like	  
domain	  (α2	  or	  ß2),	  the	  transmembrane	  region,	  and	  the	  cytoplasmic	  tail.	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MHC class Expression of 
MHC class[56] 
HLA locus Extent of 
polymorphism 
Known function 
MHC class I All nucleated 
cells and 
thrombocytes  
A Highly polymorphic Present antigens to 
CD8+ T-cells and 
form ligands for 
receptors on NK-cells. 
B 
C 
E Oligomorphic Form ligands for NK-
cell receptors. F Monomorphic 
G Oligomorphic* Inhibits effector 
functions of T-cells 
and NK-cells[57]. 









DM Oligomorphic Regulate peptide 




DP Polymorphic Present peptide 





Table	  2	  Overview	  of	  the	  different	  HLA	  isotypes,	  the	  extent	  of	  their	  polymorphism	  and	  function.	  Modified	  from	  
Parham's	  Immune	  System	  (2005)	  p.	  87,	  figure	  3.23	  and	  3.24	  [55].	  *HLA-­‐G	  is	  oligomorphic,	  but	  membrane	  
bound	  and	  soluble	  isoforms	  are	  derived	  through	  alternative	  splicing[58].	  
 
Human	  leukocyte	  antigens	  on	  platelets	  
The origin of HLA on platelets is unclear, as it could be acquired by adsorption of 
soluble plasma HLA, or most likely be integral membrane proteins derived from the 
megakaryocyte-platelet lineage [59]. It has been shown that platelets have specific 
RNA enabling them to synthesize HLA [60]. However, the platelet HLA has also 
been shown to be unable to load peptides efficiently, suggesting they have no peptide 
presenting function, and to be progressively lost by in vitro incubation at 37°C, 
suggesting a reduced expression on aged platelets [59]. Platelets have a life span of 
approximately 10 days in the circulation [61], and carry about two thirds of blood 
HLA molecules because of their high concentration [59].  
 Earlier reports suggested that differences in HLA expression between platelets 
from the same donor depended on age and if the platelets were low or high density, 
but not activation: Analysis using HLA-A2 and HLA class I specific antibodies 
showed that low density (LD) platelets carried more HLA-A2 and HLA class I than 
high density (HD) ones. LD platelets are slightly smaller than HD platelets, and so 
showed a higher surface density of HLA-class I antigens [62]. 
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 The expression of HLA class I on platelets can vary substantially between 
individuals [63-65] and is influenced by gene dosage [66]. Six genes may determine 
the platelet expression of HLA class I, two each at HLA-A, B and C loci. The HLA-
A2 molecules are the most abundant with heterozygous donors carrying 4-6,000 
molecules per platelet, and other class I molecules expressed on the surface ranges 
from 1,000 to 6,000 per gene [67]. In comparison, there is 34,000-43,000 or 19,000-
24,000 HPA-1a antigen molecules per platelet in HPA-1a homozygote and 
heterozygote platelets, respectively [67]. The average number of HLA-A,B,C reported 
varies from 15,000[62] per platelet to 81,000 [65].  
 Variation in expression of the different HLA class I isotypes is also 
significant: There are reported great individual differences between the expression of 
HLA-A2 and HLA-B[66]. Early reports suggested that the expression of HLA-C was 
very low compared to HLA-A and B [68], and due to lack of a specific antibody, few 
studies have followed to ascertain this. One study using a human IgM HLA-Cw1 
specific monoclonal antibody showed variation in expression between individuals, 
about 50% lower expression of HLA-C on platelets compared to peripheral blood 
lymphocytes, and with platelets as targets the antibody did not cause lysis in a 
complement-dependent cytotoxicity assay whereas the lymphocytes were adequately 
lysed. The study concluded with HLA-C as insignificant in immunological platelet 
transfusion refractoriness [69].  
Human	  leukocyte	  antigens	  on	  cells	  of	  the	  foetal-­‐maternal	  interface	  	  
The blastocyst formed from the fertilized egg is covered in trophoblast cells. There 
are two main subpopulations of trophoblasts: Villous trophoblasts (VT, later 
differentiating into syncytiotrophoblasts [70]) covers the villous tree and contacts 
maternal blood in the intervillous space, while the extravillous trophoblasts (EVTs) 
invade the decidua, spiral arteries and endometrium [71]. Primary VT never express 
HLA class I or II, but EVTs express the polymorphic HLA-C and the oligomorphic, 
nonclassical HLA-E and HLA-G [72].  
Soluble	  HLA	  in	  neonates	  
Soluble foetal HLA class I antigens is present in the maternal circulation from 8 
weeks of gestation [73], and is detectable in embryo cultures [74]. Most investigations 
on these plasma HLA in relation to pregnancy are measures of maternal blood 
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concentration of soluble HLA-G (sHLA-G), but one study from 1993 aimed to 
quantitate plasma HLA class I in neonates of different gestational ages [75]: Plasma 
from 93 neonates was compared with plasma from 66 healthy adults. 4 of the mothers 
had chorioamnionitis and 4 had pre-eclampsia. It is also noted that some of the 
neonates had "problems associated with prematurity". The mean plasma concentration 
in cord blood, quantitated using ELISA, was significantly lower than in adults, and 
there was no correlation between the plasma HLA levels and gestational age. Four 
different forms of HLA were detected by immunoprecipitation and immunoblotting of 
six adults and six neonates, and the distribution of these in neonates was similar to 
that in adults. Using flow cytometry, leukocytes from four adults and four neonates 
was compared, showing that the fluorescence intensities on neonatal granulocytes and 
lymphocytes was 50% of those the corresponding adult cells. The authors concluded 
that this difference could partially account for the lower concentration of HLA class I 
in neonatal plasma. It should be mentioned that no foetuses with a gestational age less 
than 24 weeks were studied. This finding was confirmed in a more recent 
investigation, where membrane bound HLA on mononuclear cells (MNCs) and sHLA 
in cord blood and adult peripheral blood was compared, using flow cytometry and 
ELISA techniques [76]. The MFI-values for membrane bound HLA I were three-fold 
lower in cord blood MNCs than in adult, but due to higher cell numbers in cord blood, 
the total quantity was not different. Soluble HLA-I was also found to be lower in cord 
blood. The authors suggested that foetal cells excrete less sHLA than adults, or that 
the foetal antigens could be less stable.  
Maternal	  leukocytes	  in	  the	  decidua	  
The mucosal lining of the uterus changes during the menstrual cycle and pregnancy, 
from endometrium to decidua. This process, known as decidualization, is induced by 
progesterone and associated with the infiltration of a unique lymphocyte population, 
including the uterine NK-cells (uNK) [71, 77]: The morphology and number of uNK 
cells change during the menstrual cycle, and nuclear changes in uNK cells indicating 
cell death is the first sign of menstrual breakdown of the decidua. Their presence is 
coincident with the period of trophoblast invasion: They accumulate around invading 
trophoblast cells in early pregnancy and progressively disappear from mid-gestation 
until absent at term. Their proliferation is stimulated by hCG [78]. The functions of 
uNK cells are unknown, but they are involved in placental trophoblast invasion and/or 
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maternal mucosal and arterial function [77], and produce cytokines like vascular 
endothelial growth factor C (VEGFC), placental growth factor (PIGF) and 
angiopoietin 2 (ANG2) [79].  
 The uNK cells constitute 70% of the infiltrating CD45+ leukocytes in the 
decidua, the rest being macrophages and T-cells, while B-cells are virtually absent 
[77].  
 The macrophages are present throughout pregnancy. They secrete 
immunoregulatory molecules, are involved with suppression of T cells and express 
inhibitory receptors that bind HLA-G dimers, found on EVTs [80-82]. They also 
actively recognize and phagocytose pathogens, an important protective mechanism 
against intrauterine infections [83].  
 Regulatory T cells (Tregs, CD4+, CD25++) are attracted by hCG [84] and 
accumulate in the decidua at a higher concentration than in peripheral blood [85]. 
Tregs mediate maternal tolerance, and their absence leads to rejection of the foetus 
[86].  
 CD8+ T cells normally produce cytotoxic molecules, but this is downregulated 
in the decidua [87].  
There are also dendritic cells (DCs) in the decidua, rendered immature or 
tolerant by progesterone. They secrete immunoregulatory cytokines promoting Tregs 
and driving the T-cell differentiation down the T-helper pathway [48, 88]. 
Uterine	  NK-­‐cell	  interactions	  with	  HLA	  expressed	  in	  the	  placenta	  	  
The role of uterine NK cells (uNK) and the immunology of pregnancy have been 
extensively reviewed by Moffet-King [77]: Maternal T-cell or antibody responses to 
trophoblast have not been convincingly shown, but uNK-cells and their expression of 
receptors for some HLA class I, could be a potential molecular mechanism for 
maternal recognition of trophoblast.  
The extravillous trophoblast (EVT) cells in the placenta express HLA-C, 
HLA-E and HLA-G. These HLA can bind and interact with killer-cell 
immunoglobulin-like receptors (KIRs) and CD94/NKG2 (on NK-cells and some T-
cells), and leukocyte Ig-like/immunoglobulin-like transcript (LIL/ILT) receptors.  
 HLA-E is the ligand for the inhibitory receptor CD94/NKG2A [89], which all 
uNK-cells express high levels of. Both trophoblast cells and surrounding maternal 
cells express HLA-E, and these interactions may prevent lysis by uNK-cells of any 
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tissue cells in the vicinity. The uNK-cells have a higher binding affinity for the 
inhibitory CD94/NKG2A than for the activating CD94/NKG2C. Binding is also 
influenced by sequences from other HLA class I bound to HLA-E, as HLA-E is 
dependent on binding with HLA-G for an affinity to activating CD94/NKG2C great 
enough to trigger the uNK-cell [90]. HLA-G is only expressed by EVTs [91], and so 
uNK-cells will interact differently with trophoblast HLA-E together with HLA-G than 
surrounding HLA-E (HLA-G negative) cells.  
 HLA-C receptors on NK cells are members of the KIR multigene family. Two 
different HLA-C groups (C1 and C2) interact with different KIRs, and KIRs specific 
for HLA-C are expressed by a greater proportion of uNK cells than peripheral-blood 
NK cells in pregnant women [92]. Each pregnancy will involve different 
combinations of paternal non-self HLA-C and maternal KIRs. Particular combinations 
of maternal KIR and HLA-C, together with foetal HLA-C groups, are overrepresented 
in women with pre-eclampsia, foetal growth restriction (FGR) and recurrent 
miscarriage[93-95], diseases of pregnancy where trophoblast invasion is defective and 
the arteries incompletely transformed (failure of placentation). Women with a KIR 
A/A genotype carrying a C2 foetus is at increased risk, especially if they themselves 
lack C2 (C1/C1 homozygote) [95]. The KIR B haplotype seems protective, and 
women with very large babies (>95th percentile) have a higher frequency of KIR B 
(Tel-B genes) [71] . In regards to FNAIT, no particular maternal KIR genes, foetal 
HLA-C genes or KIR/HLA-C combinations have been associated with HPA-1a 
alloimmunization, adverse outcome or protective effect [96]. 
 The search for a specific receptor for HLA-G on NK cells has been 
problematic, possibly due to the different characteristics of HLA-G compared to other 
HLA class I. LILRB1 (ILT2) and LILRB2 (ILT4) bind HLA-G among other HLA 
class I molecules. There is LILRB1 (ILT2) on only a small percentage of uNK cells, 
but LILRB1 (ILT2) and LILRB2 (ILT4) is also expressed on macrophages. When 
LILRB2 (ILT4) is expressed on monocytes and dendritic cells, these cells have 
reduced expression of co-stimulatory molecules and are tolerogenic [97]. APCs 
transfected with HLA-G1 has been shown to inhibit proliferation of CD4+ T-cells and 
cause them to differentiate into suppressive cells, and they shed extra HLA-G1 
molecules [98]. HLA-G can also be translated into soluble form [99], sHLA-G1, 
which has been shown to trigger in vitro apoptosis of activated CD8+ T-cells by 
interacting with the CD8-molecules and enhancing the CD95 ligand expression 
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(Fas/FasL pathway of apoptosis) [100]. Studies published more recently link a lower 
HLA-G expression and certain polymorphisms with implantation failure in IVF [101], 
pre-eclampsia [102], recurrent abortion [103], placental abruption [104] and a number 




Criteria	  for	  patients	  referred	  to	  the	  thrombocyte	  and	  leukocyte	  laboratory	  	  
Samples referred to thrombocyte and leukocyte laboratory (TRoLL) because of 
suspected FNAIT in an infant or in a previous sibling were included. This included 
pregnant mothers with a history of FNAIT, pregnant women with known or suspected 
ITP, mothers at increased risk of FNAIT because of a HPA-1a negative sister or 
mother, and children born with bleedings or low platelet count. Intrauterine foetal 
death (IUFD) investigations were included as intracranial haemorrhages can be 
caused by FNAIT, and mothers with recurrent miscarriage were also included, as this 
can be associated with alloimmunization.  
 The patients were all referred to TRoLL at Karolinska University Hospital, in 
the period from January 2007 until March 2012. The majority of referrals were from 
specialized antenatal units, delivery wards or neonatal wards.  
TRoLL	  procedures	  
In the standard investigations the patients were screened for anti-HLA class I 
antibodies with ELISA technique (OUIKSCREEN, Gen-probe GTI Diagnostics Inc, 
WI, USA). For the detection of platelet specific antibodies, PAK-12 (Gen-probe GTI 
Diagnostics) and platelet immunofluorescence test (PIFT, as described by Porcelijn 
[106] ) are used first, and then monoclonal antibody immobilization platelet assay 
(MAIPA, as described by Kiefel [107]) to confirm the initial findings. If positive for 
platelet antibodies, the parents' platelet antigens are serologically typed and in some 
cases also genotyped (IDHPA, Progenika, Barcelona, Sp). 
Analysis	  of	  anti-­‐HLA	  class	  I	  antibody	  specificities	  
After the initial screening of anti-HLA class I antibodies performed with ELISA 
techniques, some of the samples testing positive were investigated further. These were 
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samples from HPA-1a positive mothers with a thrombocytopenic child where an 
obvious cause other than alloimmunization was excluded, based on information in the 
referrals. These positive samples were then analysed by EFI accredited HLA 
laboratory (Finnish Red Cross DNA laboratory, Helsinki, Finland): All sera were 
tested for HLA class I (HLA-A,B,Cw) antibodies, analysed with Luminex 
technology-based commercial kits (LABScreen® single antigen kits, One Lambda 
Inc., Los Angeles, CA, USA). Antibodies were assigned with HLA Fusion™ software 
(One Lambda), where the strength of identified antibodies was determined by the 
mean fluorescent intensity (MFI) values of at least 1000. 
Flow	  cytometry	  investigations	  of	  HLA	  class	  I	  on	  cells	  in	  adult	  peripheral	  
blood	  and	  cord	  blood	  
Seventeen samples from presumably healthy random blood donors and seven fresh 
cord blood samples from normal deliveries at the maternity ward were stained. The 
samples were analysed on the same day as they were collected (<12 hours), and kept 
on EDTA tubes at room temperature until analysis. For the expression of HLA class I, 
anti-HLA-ABC FITC (clone w6/32, BioLegend, San Diego, CA, USA) and anti-
HLA-BC PE (clone B1.23.2, eBioscience, San Diego, CA, USA) was used, as no pan 
anti-HLA-C was available and the expression of HLA C on platelets is considered to 
be very low. Each sample was stained with either anti-HLA-ABC or anti-HLA-BC 
together with the following markers: anti-CD42a eFluor450 platelet marker (clone 
GR-P, eBioscience), anti-CD3 PE-Cy7 T cell marker (clone SK7, BD Biosciences, 
San Jose, CA, USA), and anti-CD15 PE-Cy5 neutrophil marker (clone W6D3, 
BioLegend). For compensation controls one sample for each of the five antibodies 
and one unstained sample were used. 
 The same type of standard protocol for staining was used for both adult and 
cord blood samples: 50 microliter of whole blood mixed well with antibodies and 
incubated in the dark for twenty minutes, red blood cells lysed with FACS lysing 
solution (BD Biosciences) (1mL/sample, 10 minutes), centrifuged (5 minutes with 
425 x g), washed with FACS buffer (2% FBS in PBS, 1mL/sample), centrifuged 
again and fixated with 1 % paraformaldehyde (BD Cytofix, BD Biosciences) in PBS 
(500microL/sample). 
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 The samples were analysed using a BD LSRFortessa Flow cytometer, and 
each sample was recorded with both logarithmic and arithmetic scale for FSC/SSC as 
platelets can be identified better when using the logarithmic scale. 
Analysis	  of	  data	  from	  flow	  cytometry	  
Analysis of the flow cytometry data was done with FlowJo 9.5 software (Tree Star 
Inc., Ashland, OR, USA), using the same compensation settings for all samples. 
Platelets, T cells and neutrophils were identified based on FSC/SSC characteristics 
and expression of the respective markers. The mean fluorescence intensity (MFI) of 
the anti HLA-ABC and HLA-BC staining on each cell type was taken as measure for 
the expression level. To correct for the auto fluorescence of the cells the FMO 
(fluorescence minus one) value was subtracted from the MFI: The MFI of the HLA-
BC PE stained cells recorded in the FITC channel was used as FMO for the anti-
HLA-ABC FITC stained cells and the MFI of the HLA-ABC FITC stained cells in the 
PE-channel served as FMO for the HLA-BC PE stained cells. The ratio of these 
values was again used to compare the expression of HLA-A and HLA-B/HLA-BC in 
the different types of cells and in the different samples.  
 The data is shown in tables and charts using the HLA-MFI-FMO values to 
show the mean and the variation between cells of different donors. 
Sub-­‐analysis	  of	  data	  from	  the	  antibody	  specificity	  assay	  
The analysis of the HLA antibody specificities in the Luminex-based single antigen 
assay is a semi-quantitative method, where the normally used cut-off is an MFI value 
higher than 1000. Here, two cut-offs were used and the high MFI values of the 
different specificities divided into >15,000 and >10,000-14,999, named high positive 
and medium positive, respectively. The number of specificities each patient then 
tested positive for with the two cut-offs was counted and presented in histograms. To 
determine which specificities were the most common, the specificities with a number 
of patients testing positive higher than the average number of patients per specificity 
were selected and presented in histograms. If a specificity stood out as common in the 
medium group, but not in the high positive group, they were still included in both 
histograms to reflect the variation of MFI values in the different specificities. The 
different specificities with the high positive cut-off were also stratified by HLA 
isotype. 
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HLA	  allele	  frequencies	  
To estimate the frequency of the different alleles, the Allele Frequency Net Database 
was used (www.allelefrequencies.net). The different alleles was plotted in the search 
boxes together with "Ethnic origin = Caucasoid". As there was no data from an 
unselected Swedish population, data from countries of similar ethnicity (Austria, 
Australia New South Wales Caucasian, England North West, Finland) was selected to 
complement the selected Swedish data available (Southern and Northern Sami).  
Charts	  
All histograms were created using Microsoft Excel 2011 version.14.0.0. Box plots 
were created using IBM SPSS Statistics version 19.0.0.   
Results	  	  
Patients	  referred	  to	  TRoLL	  and	  results	  of	  initial	  analysis	  
Out of 260 patients referred, 113 (113/260 = 43.5%) had detectable anti-platelet 
antibodies. The majority of these (80%, 90/113 patients) tested positive for anti-HLA 
class I antibodies: 27 patients (27/113 = 24%) tested positive for anti-HLA class I in 
combination with anti-HPA antibodies, 63 patients (63/113 = 56%) for anti-HLA 
class I antibodies alone. 23 mothers only tested positive for anti-HPA antibodies: A 
group of 16 (16/113 = 14%) mothers with anti-HPA antibodies and thrombocytopenic 
children, and another six mothers with known ITP who tested positive for platelet 
antibodies with weak or unspecific reactions. One mother without a history of ITP 
tested positive for autoreactive platelet antibodies. These seven women (7/113 = 5%) 
constitute the "autoreactive anti-HPA antibodies" group in figure 2.  
 In cases where there was a HPA antigen mismatch between mother and father, 
and/or platelet specific (HPA) antibodies were detected in the mother of a 
thrombocytopenic child, FNAIT was diagnosed or suspected.  
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Figure	  2	  The	  different	  types	  of	  antibodies	  detected	  in	  113	  out	  of	  260	  (44%)	  referred	  patients	  testing	  positive.	  
aHLA	  class	  I	  ab	  =	  anti-­‐HLA	  class	  I	  alloantibodies.	  aHPA	  ab	  =	  anti-­‐HPA	  alloantibodies.	  Autoreactive	  ab	  =	  
Antibodies	  reactive	  with	  the	  mother's	  own	  platelets.	  
 
Of the ones testing positive for platelet specific (HPA) antibodies (excluding the 
autoreactive group), 16/43 (37%) did not have anti-HLA class I antibodies. Anti-
HPA-1a was the most common platelet specific antibody (30/43 = 70%). There were 
3 patients testing positive for anti-HPA-5b antibodies (3/43 = 7%), and 2 (2/43 = 5%) 
testing positive for anti-HPA-3a antibodies. There were 8 patients with suspected anti-
HPA-15 antibodies, but only one sample from one patient (1/43 = 2%) had been 
confirmed in a reference lab. 
Outcomes	  of	  cases	  with	  suspected	  FNAIT	  
There were no intracranial haemorrhages detected by the time of referral in the 
children of these HPA-1a alloimmunised women. However, one mother was referred 
because her previous child had cerebral palsy without any known cause. She was 
HPA-1a positive, had antibodies with GPIIb/IIIa and HPA-5b specificity and anti-
HLA class I antibodies reactive against the father's platelets.   
 13/43 (30%) presented with petechiae, and/or haematomas. There was one 
child with unspecified bleeding by 3 weeks of age, where the mother tested positive 
for both anti-HLA class I and aHPA-1a antibodies. There was also one case of a child 
born with pulmonary adaption syndrome, thrombocytopenia, and CRP = 6 with 
negative cultures who had bloody stools after 1 day. Two mothers gave birth to twins. 
In one, both children were affected with thrombocytopenia and skin bleedings, and in 





Anebodies	  (ab)	  detected	  
aHLA	  class	  I	  ab	   aHPA	  and	  aHLA	  class	  I	  
aHPA	  ab	   AutoreacQve	  aHPA	  ab	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monochorionic twins. In 25/43 (58%) referrals there were thrombocytopenic children 
without symptoms noted.  
 
In the "autoreactive anti-HPA antibodies" group (not included in the group of 
suspected cases of FNAIT), five mothers diagnosed with ITP were referred during 
pregnancy, and delivered healthy children. One mother had antibodies of GPIIb/IIIa 
specificity reactive to her own platelets, and a child with suspected massive ICH.   
   
Table	  3	  Outcomes	  in	  patients	  testing	  positive	  for	  anti-­‐HPA	  antibodies,	  alone	  or	  together	  with	  anti-­‐HLA	  class	  I	  
antibodies,	  including	  both	  the	  group	  of	  suspected	  FNAIT	  (43	  patients)	  and	  the	  autoreactive	  group	  (7	  patients).	  
*One	  mother	  with	  HPA	  antibodies	  reactive	  with	  GPIIb/IIIa	  on	  her	  own	  platelets	  gave	  birth	  to	  a	  child	  with	  
suspected	  massive	  ICH.	  None	  of	  the	  mothers	  with	  ITP	  gave	  birth	  to	  thrombocytopenic	  children.	  aHLA	  class	  I	  ab	  
=	  anti-­‐HLA	  class	  I	  alloantibodies.	  aHPA	  ab	  =	  anti-­‐HPA	  alloantibodies.	  CP=Cerebral	  palsy.	  ITP=Immune	  
thrombocytopenic	  purpura.	  	  
	  
Patients	  testing	  positive	  for	  anti-­‐HLA	  class	  I	  antibodies	  alone	  
The mothers testing positive for anti-HLA class I antibodies only were divided into 
two groups: The first included those with other plausible causes of thrombocytopenia 
in the referrals, or where thrombocytopenia was not confirmed. The other those where 
the child was said to be thrombocytopenic and no information on factors causing or 
contributing to this was given, and where alloimmunization so could be a likely cause. 
 
Cases of possible alloimmunization: 
In the latter group a total of 26 referred mothers fit the criteria. Three of these mothers 
where HPA-1a negative: One gave birth to a child with suspected FNAIT, but there 
was never anti-HPA-1a antibodies detected. Another gave birth to a twin with 





aHLA class I ab Total 
ICH* 1 0 1 
Previous child with CP 0 1 1 
Petechiae 3 4 7 
Haematoma and petechiae 2 4 6 
Unspec. bleeding 3 weeks postpartum 0 1 1 
Bloody stools 0 1 1 
Twins with bleedings 1 0 1 
Twins with one thrombocytopenic 
child 0 1 1 
No bleedings noted 10 15 25 
Mothers with ITP 6 0 5 
Total 23 27 50 
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suspected ICH in 34 weeks of gestation. One was referred because her sister had 
given birth to a child with FNAIT, and had herself anti-HPA-1a antibody levels just 
under the cut-off value together with "strong" anti-HLA class I antibodies in two 
pregnancies. However, there was no information on treatment or complications in her 
pregnancies. 
 There were also other HPA-incompatibilities between mother and father in 
this group of patients. One mother was HPA-1b and HPA-15 negative, and the father 
positive for both. In another couple the mother and father were HPA-3a negative and 
positive, respectively.   
 Of the 23 HPA-1a positive mothers, 8 (35%) gave birth to children with 
bleedings varying from petechiae to ICH. One mother had given birth to two 
thrombocytopenic children: One boy with multiple subdural hematomas and a platelet 
count of 32, and later a girl with platelet count = 15 x 109/L, but without any ICH 
(screened with ultrasound). Both children were said to be healthy at the time of 
referral. One mother delivered a term boy with extra - and intracranial haemorrhages 
after vacuum extraction. He had a low platelet count and normal coagulation tests. 
Another mother had a history of drug-induced ITP more than ten years before the 
birth of a child with petechiae and scalp haematoma, with nadir platelet count = 
10x109/L. She tested positive for anti-HLA class I antibodies together with weak 
reacting platelet antibodies without known specificity. One mother with preeclampsia 
had a child with unspecified bleedings and a low platelet count that died within one 
month of life. She was found to be HPA-3a negative and the father HPA-3a positive, 
but only tested positive for anti-HLA class I antibodies. The last child born with 
bleedings was a girl with petechiae in the face, chest, trunk and groin, but was 
otherwise well. She had a moderate thrombocytopenia with platelet counts 48-51-45 x 
109/L. One boy born to term had a nadir platelet count =17 x109/L. He did not 
respond to platelet transfusion or IVIG. 
 Three of the children of the 23 HPA-1a positive mothers (13%) were said to 
be small for gestation age or growth restricted. One was delivered with ECS, and had 
hypoglycemia/hyperinsulinism together with thrombocytopenia. He was transfused 
and diagnosed with transient thrombocytopenia. One of the other SGA children with 
hypoglycemia, also had apnoea. The last SGA child was transfused (not noted if this 
was with compatible platelets or not) but with little effect, with a platelet count of 
21/25 x 109/L before/after transfusion. One child presented with thrombocytopenia 
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and hyperbilirubinemia three days post partum, tested DAT negative. The rest of the 
children of the 23 HPA-1a mothers did not have any symptoms or other findings aside 
from thrombocytopenia noted in their referrals.  
 
Patients referred with other plausible causes:  
In this group the 37 patients referred either had other factors that could contribute to 
thrombocytopenia in the child, thrombocytopenia was not confirmed or the referral 
for the detection of thrombocyte antibodies was for other reasons.    
HPA-­‐1a	  negative	  mothers	  referred	  also	  tested	  negative	  for	  alloantibodies	  	  
Out of 260 patients, there were no antibodies detected in 147 (57%). This group was 
further divided into subgroups based on available information in the referrals and 
HPA-1a antigen status. 
 There were 11 (11/147) patients found to be HPA-1a negative: Three of these 
had given birth to a thrombocytopenic child. The lowest platelet count was 7 x 109/L, 
19 x109/L and unknown. One boy born with hypoxia was given two platelet 
transfusions with only a temporary rise in platelet count. A girl was born at term with 
a tendency towards hypoglycemia, but otherwise well. The last child (unknown 
gender) was born with respiratory distress syndrome and a birth weight of 2.3 kg 
(unknown week of gestation). There were also two HPA-1a negative mothers with 
previous immunisations in earlier pregnancies tested during a new pregnancy. One 
had earlier given birth to a thrombocytopenic child. Three other HPA-1a negative 
mothers were tested during pregnancy without detectable alloantibodies, one had 
previously given birth to a child without thrombocytopenia. One 40 year old HPA-1a 
negative mother tested during pregnancy had been treated with IVIG during the 
pregnancy of her first born child, she had been pregnant a total of 7 times (7 gravida, 
1 para). A HPA-1a negative mother with preeclampsia gave birth to a child with 
petechiae and a platelet count of 185 x 109/L. After a few days the child had 
thrombocytopenia together with erythema toxicum, but the platelet count rose again 
with the disappearance of the skin lesions. There was also one sample from a 5 days 
old child with suspected FNAIT, but no antibodies were detected.  
 One group of HPA-1a positive mothers gave birth to thrombocytopenic 
children without any other obvious causes involved: In 49% of the referrals a platelet 
count was given, the other referrals were noted with “thrombocytopenic child”. The 
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average nadir platelet count was 32 x 109/L. 35% (15/43) had a platelet count less 
than 50 x 109/L, 19% (8/43) a platelet lower than 20 x 109/L. The range was 6-94 x 
109/L and the mean platelet count 30 x 109/L. There was one case of suspected ICH in 
this group, a boy with severe thrombocytopenia, haematuria and ICH immediately 
after delivery. Seven children had haematomas and/or petechiae. One of these 
children was the third child of a mother whose first child was born with haematoma 
and died, the second was born healthy and child number three was delivered by 
emergency caesarean because of threatening asphyxia and had multiple haematomas 
at delivery. Another mother was referred because of HPA-3a antigen testing: Her 
second child was born with a plt count <1x109/L and several bleedings and petechiae, 
but was alive and well by the time of referral four years later. Both parents were 
HPA-1a and HPA-3a positive and HPA-5b negative. Eleven couples did have other 
HPA-antigen incompatibilities between mother and father, with HPA-5b being the 
most common one (7 couples).  
 The other groups of patients testing negative were divided into further 
subgroups and are presented in the flowchart (figure 3). 
Platelet	  count,	  foetal	  gender	  and	  maternal	  age	  in	  the	  different	  groups	  
To compare the outcome of the different patients, three groups were selected: Those 
were an HPA-1a incompatibility and HPA-1a positive antibodies were detected, 
meaning likely cases of FNAIT, with and without HLA class I antibodies. The last 
group consisted of the patients with thrombocytopenic children and no other findings 
than thrombocytopenia in a newborn child and a mother testing positive for anti-HLA 
class I antibodies (see "cases of possible alloimmunization").  
 The platelet counts given in the referrals were mostly indicative of severe 
cases of thrombocytopenia, with an average platelet count of <30 x 109/L in all 
groups. The platelet counts were slightly higher in the HLA class I only group 
compared to those with HPA-1a antibodies. The mean platelet count was lowest in the 
group testing positive for both anti-HLA class I and anti-HPA-1a antibodies, although 
this was not tested statistically. 
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Positive antibodies  HLA class I and HPA-1a  HPA-1a  only HLA class I only* 
No of patients 21 9 26 
Platelet counts 9 6 48 
 
9 38 15 
 
4 72 10 
 
13 5 44 
 
8 5 17 
 

















  Percentage of patients with 
platelet count 52.4 66.7 30.8 
% of patients with plt < 50 47.6 55.6 30.8 
% of patients with plt <20 33.3 33.3 11.5 
Mean platelet count 20.5 25.0 27.4 
Median platelet count 10.0 15.0 25.5 
Range plt count 3-60 5-72 10-48 
Table	  4	  Platelet	  counts	  (x109/L)	  in	  different	  groups	  of	  patients	  testing	  positive	  for	  alloantibodies.	  *Three	  
patients	  were	  HPA-­‐1a	  negative,	  one	  of	  these	  children	  had	  a	  platelet	  count	  nadir	  of	  34	  x	  109/L.	  HLA	  class	  I	  and	  
HPA-­‐1a	  =	  patients	  with	  both	  anti-­‐HLA	  class	  I	  and	  anti-­‐HPA-­‐1a	  antibodies.	  HPA-­‐1a	  only	  =	  Patients	  with	  only	  anti-­‐
HPA-­‐1a	  antibodies.	  HLA	  class	  I	  only	  =	  Patients	  testing	  positive	  for	  only	  anti-­‐HLA	  class	  I	  antibodies.	  
 
Foetal gender 
There were more boys than girls in the population of referred patients, although a 
minority (23%) of the referrals in these groups had information on foetal gender. In 
total, ten out of thirteen children with known gender (77%) were boys. The proportion 
of boys when known gender was highest in the group testing positive for both anti-
HLA class I and anti-HPA-1a antibodies, with 6/6 referred children boys. 
 
Positive antibodies HLA class I and HPA-1a HPA-1a only HLA class I only 
No of patients 21 9 26 
Known foetal gender 6  2 5 
Boy neonate 6 1 3 
Table	  5	  Foetal	  gender	  in	  different	  groups	  of	  patients.	  In	  the	  HLA	  class	  I	  only	  group	  the	  HPA-­‐1a	  negative	  
mothers	  are	  included.	  Known	  foetal	  gender	  =	  Foetal	  gender	  given	  in	  the	  referral.	  HLA	  class	  I	  and	  HPA-­‐1a	  =	  
patients	  with	  both	  anti-­‐HLA	  class	  I	  and	  anti-­‐HPA-­‐1a	  antibodies.	  HPA-­‐1a	  only	  =	  Patients	  with	  only	  anti-­‐HPA-­‐1a	  
antibodies.	  HLA	  class	  I	  only	  =	  Patients	  testing	  positive	  for	  only	  anti-­‐HLA	  class	  I	  antibodies.	  
 
Maternal age 
The mothers in the different groups of referred patients seem to be of the same age, 
although possibly higher in the anti-HLA class I antibodies only group. The parity of 
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the women was not known. For comparison, the average age of mothers giving birth 
in Sweden 2011 was 30.3 years, independent of parity [108]. 
 
Positive antibodies HLA class I and HPA-1a HPA-1a only HLA Class I only 
No of patients 21 9 26 
Age range 22 - 43 24 - 38 19 - 42 
Average age 31 31 32 
Median age 30 32 33 
Table	  6	  Maternal	  age	  in	  the	  different	  groups.	  HPA-­‐1a	  negative	  mothers	  are	  included	  in	  the	  HLA	  class	  I	  only	  
group.	  HLA	  class	  I	  and	  HPA-­‐1a	  =	  patients	  with	  both	  anti-­‐HLA	  class	  I	  and	  anti-­‐HPA-­‐1a	  antibodies.	  HPA-­‐1a	  only	  =	  
Patients	  with	  only	  anti-­‐HPA-­‐1a	  antibodies.	  HLA	  class	  I	  only	  =	  Patients	  testing	  positive	  for	  only	  anti-­‐HLA	  class	  I	  
antibodies.	  
 
Cases of intracranial haemorrhage 
Since intracranial haemorrhaging is the worst-case scenario for children with 
thrombocytopenia, it is a reason for referral for the detection of thrombocyte 
antibodies in mothers when ICH is suspected during a pregnancy. Out of 261 referred 
patients, 13 (5%) had suspected or confirmed ICH in a foetus or newborn, while 4 
(1.5%) patients had a previous child that suffered ICH, making a total of 6.5% 
(17/261) occurrence of ICH in the referrals. Six of these (35%) had anti-HLA class I 
antibodies, one (5.9%) had autoreactive aHPA antibodies, and ten (59%) had no 
antibodies detected.  
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Figure	  3	  Flowchart	  describing	  260	  patients	  referred	  to	  the	  thrombocyte	  and	  leukocyte	  laboratory	  (TRoLL),	  Karolinska	  
University	  Hospital,	  in	  the	  period	  of	  January	  2007	  to	  March	  2012.	  The	  patients	  are	  sorted	  after	  antibody	  findings	  and	  clinical	  




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	   29	  
The	  most	  frequent	  anti-­‐HLA	  class	  I	  antibody	  specificities	  
In most of the 23 patient samples, a broad spectrum of anti-HLA class I antibodies 
were detected and termed positive with the high (MFI >/= 15,000) and medium (MFI 
>10,000-14,999) cut-offs, and so the number of patients testing positive per 
specificity was quite evenly distributed with a range of 0 to 11 for all 97 specificities 
tested. The average number of patients testing positive per specificity was 1.88 in the 
medium group and 3.54 in the high group. 
 Anti-HLA class I antibodies of the HLA-B isotype was the most common 
antibody specificity, meaning with the highest number of patients testing positive 
using the high and medium cut-offs. The most common antibody specificities were 
HLA B*07:02, B*13:01, B*13:02, B*27:05, B*40:01, B*40:02, B*40:06, B*48:01, 
B*50:01, B*57:01, B*57:03 and B*58:01.  
 When searching in the allele frequency net database [109], these alleles seem 
rare with a frequencies of about 5% or lower, with the exception of HLA B*07:02 
(about 15%), see table 7. 
 In the anti-HLA antibody specificity assay the HLA-B antibodies were also 
the most tested, with 50/97 (52%) specificities being of the HLA-B type. It was tested 
for 31 (32%) and 16 (16%) HLA-A and HLA-C specificities, respectively.  
 HLA-B antibodies were also stratified on whether they were Bw6 or Bw4 
reactive, and 54% of the high positive (MFI >/= 15,000) HLA-B antibodies were Bw6 
reactive, and 46% Bw4 reactive ones. 
	  
Table	  7	  Antibodies	  detected	  with	  the	  highest	  number	  of	  patients	  positive.	  *Allele	  frequencies	  in	  Austria,	  
Australia	  New	  South	  Wales	  Caucasian,	  England	  North	  West,	  Sweden	  North/South	  Sami,	  Finland.	  ND	  =	  No	  data.	  
Antibody 
specificity 
Total no of patients 
positive (% of 23) 
Proportion of high 
positive  
Allele frequencies (%) 
in a general population* 
B*07:02 9 (39%) 5/9 high positive 13-12-15-19/19-14 
B*13:01 9 (39%) 6/9 high positive 0.8-0.0-ND-ND/1.2-ND 
B*13:02 9 (39%) 6/9 high positive 4.8-0.8-0.7-ND/ND-1.7 
B*27:05 10 (43%) 6/10 high positive 3.8-4.5-4.2-20/10-6.1 
B*40:01 10 (43%) 7/10 high positive 3.0-7.9-6.0-14/10-9.4 
B*40:02 11 (48%) 8/11 high positive 2.0-0.8-0.5-8.4/3.9-1.7 
B*40:06 10 (43%) 4/10 high positive ND-0.0-ND-ND-ND 
B*48:01 11 (48%) 7/11 high positive ND-0.0-0.2-0.7/ND-ND 
B*50:01 11 (48%) 6/11 high positive 1.8-0.8-1.7-ND/ND-ND 
B*57:01 10 (43%) 8/10 high positive 2.8-0.0-ND-0.3/1.9-1.7 
B*57:03 10 (43%) 8/10 high positive 0.2-ND-ND-ND/ND-ND 
B*58:01 9 (39%) 9/9 high positive 0.8-4.9-0.5-ND/ND-ND 
	   30	  
 
Figure	  4	  Histogram	  of	  the	  different	  specificities	  with	  most	  patients	  testing	  positive.	  The	  blue	  bars	  denote	  the	  
number	  of	  patients	  testing	  positive	  with	  high	  (MFI	  >/=	  15,000)	  cut-­‐off,	  and	  the	  red	  bars	  the	  number	  of	  patients	  
testing	  positive	  with	  the	  medium	  (MFI>10,000-­‐14,999)	  cut-­‐off.	  	  
 
 
Figure	  5	  Anti-­‐HLA	  class	  I	  antibody	  specificity	  sorted	  by	  HLA	  isotype,	  using	  MFI	  >/=	  15,000	  as	  cut-­‐off.	  
 
Distribution	  of	  anti-­‐HLA	  class	  I	  antibody	  specificities	  in	  the	  different	  patients	  
 When using the set cut-off, two and one patient tested negative with the high 
and medium cut-offs, respectively. Eleven patients (43%) tested positive for less than 
10 specificities with the high cut-off. However, nine patients (39%) then tested 
positive for more than 20 specificities. The average number of (high) positive 
specificities per patient was 14.9, with a range of 0 to 41 and a median of 14 
specificities.  
  Some patients had generally lower MFI values, but with one or two 
specificities with higher values than the cut-off (see figure 6).  
 The high positive specificities were also stratified based on HLA isotype. 




aHLA	  anebodies	  sorted	  by	  isotype	  
High	  posieve	  
HLA-­‐A	   HLA-­‐B	   HLA-­‐C	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patients (8.7%) tested positive for anti-HLA-C only, and one (4.3%) only for anti-
HLA-A. Eight patients (35%) had a combination of anti-HLA-A and anti-HLA-B 
antibodies, one (4.3%) had anti-HLA-B and anti-HLA-C, and four (17%) a 
combination of all three.  
 Most of the patients had both Bw6 and Bw4 reactive anti-HLA-B antibodies 
(high positive). Five patients (22%) had only Bw6 reactive ones, three (13%) only 
Bw4 reactive and the rest (65%) a combination of the two.  
 The two patients with HPA-1b and HPA-15, and HPA-3a incompatibilities 
both tested positive for a low number of anti-HLA antibody specificities. Patient 17 
with HPA-1b and HPA-15 incompatibility tested negative with both cut-offs, while 
patient 6 with HPA-3a incompatibility tested positive for seven specificities using the 
two cut-offs. 
	  
Figure	  6	  Number	  of	  antibody	  specificities	  testing	  positive	  in	  the	  different	  patients.	  The	  blue	  bars	  denote	  the	  
number	  of	  specificities	  testing	  positive	  with	  high	  (MFI	  >/=	  15,000)	  cut-­‐off,	  and	  the	  red	  bars	  the	  number	  of	  
specificities	  testing	  positive	  with	  the	  medium	  (MFI>10,000-­‐14,999)	  cut-­‐off.	  
	  
Figure	  7	  The	  different	  anti-­‐HLA	  class	  I	  antibody	  isotypes	  in	  the	  different	  patients,	  using	  the	  high	  (MFI	  >/=	  
15,000)	  cut-­‐off.	  The	  green	  bar	  denotes	  the	  number	  of	  positive	  antibodies	  of	  HLA-­‐C	  isotype,	  the	  red	  bar	  denotes	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Expression	  of	  HLA	  on	  platelets,	  neutrophils	  and	  T-­‐cells	  in	  adult	  peripheral	  
blood	  and	  umbilical	  cord	  blood	  
The HLA-ABC and HLA-BC MFI-FMO values for each cell type in the different 
populations and for each individual's different cell types showed great variation.  
As a whole, T-cells had the highest expression of HLA-ABC and HLA-BC (highest 
MFI-FMO values) in both adults and cord blood populations, and platelets the lowest.  
	  
Table	  8	  The	  mean	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐FMO	  values	  of	  the	  different	  cell	  types	  in	  adult	  and	  cord	  blood,	  and	  
the	  ratios	  between	  these	  mean	  values	  in	  the	  two	  groups.	  	  
 
The mean ratio between HLA-BC/HLA-ABC was largest on T-cells for both adult 
and cord blood, with ratio being 1.74 (range 0.62-3.37) in adult T-cells and 0.54 
(range 0.31-1.10) in cord blood T-cells. The ratios of HLA-BC/HLA-ABC per cell 
type seemed larger in the adult samples compared to the cord blood samples, implying 

































295.2	   188.8	   0.67	  	  
(0.44-­‐1.11)	  












































1.5697	  =	  157% 0.7185	  =	  72% 
Neutrophils	  
(CD15)	  
1.9821	  =	  198% 0.5135	  =	  51% 
T-­‐cells	  	  
(CD3)	  
1.6678	  =	  167	  %	   0.5793	  =	  58% 
Table	  10	  Cord	  blood	  and	  adult	  blood	  mean	  HLA-­‐
ABC	  MFI-­‐FMO	  and	  HLA-­‐BC	  MFI-­‐FMO	  compared	  in	  





































0.4475	  =	  45% 0.3766	  =	  38% 0.2887	  =	  29% 0.3256	  =	  33% 
Table	  9	  The	  mean	  MFI-­‐FMO	  values	  of	  platelets	  and	  neutrophils	  
compared	  to	  the	  values	  of	  the	  T-­‐cells	  in	  the	  two	  groups	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Cord blood cells also had higher HLA-ABC and lower HLA-BC compared to each 
adult cell type. The difference was in both cases greatest in the neutrophils, where the 
cord blood had nearly double the HLA-ABC and half the HLA-BC compared to adult 
blood. In platelets, the cord blood had 57% more HLA-ABC, and 28% less HLA-BC, 
while for T-cells the cord blood had 67% more HLA-ABC and 42% less HLA-ABC.  
 
The HLA-ABC and HLA-BC MFI values were highest on the T-cells. Using the T-
cells as reference, the cord blood platelets and adult platelets both had 11% of the 
HLA-ABC MFI-FMO, and 5.6% and 4.5% of the HLA-BC MFI-MFO. Comparing 
neutrophils to T-cells, the cord blood and adult blood expressed 45% and 38% of the 
HLA-ABC, and 29% and 33% of the HLA-BC. The adult and cord blood seem 
similar in respect to the relationship of different levels of HLA-ABC and BC between 
the different types of cells.  
 
When looking at the individual MFI-FMO values, there is a great variation. The 
widest range of MFI-FMO values for both HLA-ABC and HLA-BC was in adult and 
cord blood T-cells. In cord blood T-cells the range was greater in HLA-ABC values 
(range 2298-8320 versus 940-4752 in HLA-BC values), while in adult blood T-cells 
the range was greater in HLA-BC values with a range of 1594-8085 compared to 674-
4769 in HLA-ABC values. The least variation was in platelet MFI-FMO values. Here, 
the range in HLA-ABC and BC values in cord blood was 332-654 and 58-325, 
respectively. In adults the ranges for MFI-FMO values were greater, with HLA-ABC 
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Platelets	  
	  





Figure	  8	  The	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐MFO	  mean	  values	  
for	  donor	  1	  to	  17	  is	  shown	  together	  with	  mean	  values	  for	  
all	  the	  adult	  samples.	  Blue	  diamonds	  denote	  each	  donor's	  
mean	  HLA-­‐ABC	  MFI-­‐FMO	  value,	  and	  red	  squares	  each	  
donor's	  mean	  HLA-­‐BC	  MFI-­‐FMO	  value.	  The	  two	  values	  for	  
each	  donor	  are	  marked	  along	  the	  same	  vertical	  axis.	  Green	  
line	  =	  Mean	  HLA-­‐ABC	  MFI-­‐FMO	  for	  all	  adult	  donors.	  Purple	  
line	  =	  Mean	  HLA-­‐BC	  MFI-­‐FMO	  for	  all	  adult	  donors.	  
Figure	  9	  Mean	  values	  for	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐MFO	  on	  
platelets	  in	  the	  individual	  cord	  blood	  (CB)	  samples	  (n=8)	  is	  
shown	  together	  with	  the	  total	  mean	  values.	  Blue	  diamonds	  
denote	  each	  CB's	  mean	  HLA-­‐ABC	  MFI-­‐FMO	  value,	  and	  red	  
squares	  each	  CB's	  mean	  HLA-­‐BC	  MFI-­‐FMO	  value.	  The	  two	  
values	  for	  each	  CB	  are	  marked	  along	  the	  same	  vertical	  axis.	  
Green	  line	  =	  Mean	  HLA-­‐ABC	  MFI-­‐FMO	  for	  all	  CB	  samples.	  
Purple	  line	  =	  Mean	  HLA-­‐BC	  MFI-­‐FMO	  for	  all	  CB	  samples.	  	  










































Figure	  10	  Histograms	  of	  HLA-­‐ABC	  FITC	  and	  HLA-­‐BC	  PE	  MFI	  on	  cord	  blood	  
and	  adult	  platelets.	  The	  donors	  with	  highest	  and	  lowest	  MFI	  values	  
were	  selected.	  Each	  donor	  is	  represented	  by	  a	  different	  colour,	  with	  the	  
same	  colour	  in	  both	  charts.	  
Figure	  11	  Box	  plot	  with	  the	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐FMO	  
values	  for	  adult	  and	  cord	  blood	  platelets,	  shown	  with	  
median	  (horisontal	  lines),	  interquartile	  range	  (boxes),	  
maximum	  and	  minimum	  values	  as	  whiskers,	  outliers	  (°)	  
and	  extreme	  outliers	  (*).	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Figure	  12	  Mean	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐FMO	  values	  on	  
neutrophils	  in	  random	  blood	  donors	  (17),	  together	  with	  
mean	  values	  for	  all	  adult	  donors.	  Blue	  diamonds	  denote	  
each	  donor's	  mean	  HLA-­‐ABC	  MFI-­‐FMO	  value,	  and	  red	  
squares	  each	  donor's	  mean	  HLA-­‐BC	  MFI-­‐FMO	  value.	  The	  two	  
values	  for	  each	  donor	  are	  marked	  along	  the	  same	  vertical	  
axis.	  Green	  line	  =	  Mean	  HLA-­‐ABC	  MFI-­‐FMO	  for	  all	  adult	  
donors.	  Purple	  line	  =	  Mean	  HLA-­‐BC	  MFI-­‐FMO	  for	  all	  adult	  
donors.	  
Figure	  13	  Mean	  values	  for	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐MFO	  on	  
neutrophils	  in	  the	  different	  cord	  blood	  (CB)	  samples	  (n=8)	  is	  
shown	  together	  with	  the	  total	  mean	  values.	  Blue	  diamonds	  
denote	  each	  CB's	  mean	  HLA-­‐ABC	  MFI-­‐FMO	  value,	  and	  red	  
squares	  each	  CB's	  mean	  HLA-­‐BC	  MFI-­‐FMO	  value.	  The	  two	  
values	  for	  each	  CB	  are	  marked	  along	  the	  same	  vertical	  axis.	  
Green	  line	  =	  Mean	  HLA-­‐ABC	  MFI-­‐FMO	  for	  all	  CB	  samples.	  
Purple	  line	  =	  Mean	  HLA-­‐BC	  MFI-­‐FMO	  for	  all	  CB	  samples.	  


































Figure	  14	  Histograms	  of	  HLA-­‐ABC	  FITC	  and	  HLA-­‐BC	  PE	  MFI	  values	  on	  
adult	  and	  cord	  blood	  neutrophils.	  The	  donors	  with	  highest	  and	  lowest	  
MFI	  values	  were	  selected.	  Each	  donor	  is	  represented	  by	  a	  different	  
colour,	  with	  the	  same	  colour	  in	  both	  charts.	  
	  
Figure	  15	  Box	  plot	  with	  the	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐FMO	  
values	  for	  adult	  and	  cord	  blood	  neutrophils,	  shown	  with	  
median	  (horisontal	  lines),	  interquartile	  range	  (boxes),	  
maximum	  and	  minimum	  values	  as	  whiskers,	  outliers	  (°)	  
and	  extreme	  outliers	  (*).	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Figure	  16	  Mean	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐FMO	  values	  on	  T-­‐
cells	  in	  random	  blood	  donors	  (17),	  together	  with	  mean	  
values	  for	  all	  adult	  donors.	  Blue	  diamonds	  denote	  each	  
donor's	  mean	  HLA-­‐ABC	  MFI-­‐FMO	  value,	  and	  red	  squares	  
each	  donor's	  mean	  HLA-­‐BC	  MFI-­‐FMO	  value.	  The	  two	  values	  
for	  each	  donor	  are	  marked	  along	  the	  same	  vertical	  axis.	  
Green	  line	  =	  Mean	  HLA-­‐ABC	  MFI-­‐FMO	  for	  all	  adult	  donors.	  
Purple	  line	  =	  Mean	  HLA-­‐BC	  MFI-­‐FMO	  for	  all	  adult	  donors.	  
Figure	  17	  Mean	  values	  for	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐
MFO	  on	  T-­‐cells	  in	  the	  different	  cord	  blood	  (CB)	  
samples	  (n=8)	  is	  shown	  together	  with	  the	  total	  mean	  
values.	  Blue	  diamonds	  denote	  each	  CB's	  mean	  HLA-­‐
ABC	  MFI-­‐FMO	  value,	  and	  red	  squares	  each	  CB's	  mean	  
HLA-­‐BC	  MFI-­‐FMO	  value.	  The	  two	  values	  for	  each	  CB	  
are	  marked	  along	  the	  same	  vertical	  axis.	  Green	  line	  =	  
Mean	  HLA-­‐ABC	  MFI-­‐FMO	  for	  all	  CB	  samples.	  Purple	  
line	  =	  Mean	  HLA-­‐BC	  MFI-­‐FMO	  for	  all	  CB	  samples.	  
















































Figure	  18	  Histograms	  of	  HLA-­‐ABC	  FITC	  and	  HLA-­‐BC	  PE	  MFI	  values	  on	  
adult	  and	  cord	  blood	  T-­‐cells.	  The	  donors	  with	  highest	  and	  lowest	  MFI	  
values	  were	  selected.	  Each	  donor	  is	  represented	  by	  a	  different	  colour,	  
with	  the	  same	  colour	  in	  both	  charts.	  
	  
Figure	  19	  Box	  plot	  with	  the	  HLA-­‐ABC	  and	  HLA-­‐BC	  MFI-­‐FMO	  
values	  for	  adult	  and	  cord	  blood	  T-­‐cells,	  shown	  with	  
median	  (horisontal	  lines),	  interquartile	  range	  (boxes),	  
maximum	  and	  minimum	  values	  as	  whiskers,	  outliers	  (°)	  
and	  extreme	  outliers	  (*).	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Discussion	  
Patients	  referred	  for	  detection	  of	  alloantibodies	  
Alloantibodies were detected in 113/260 (43%) of referrals (including suspected 
HPA-15 antibodies). 90 patients (35% of patients) tested positive for anti-HLA 
antibodies, of these 63 (70%) alone and 27 (30%) with HPA-1a. 23/260 patients 
(8.8%) had only HPA antibodies (including 7 patients with autoreactive ones). FNAIT 
was diagnosed, based on verified detection of anti-HPA alloantibodies, in 35/260 
(13.5%) patients (not including 8 cases of suspected HPA-15 alloimmunization). 
These numbers suggest that even in patients referred on clinical suspicion, FNAIT 
with detectable antibodies is quite rare, and that anti-HLA antibodies are more 
common during pregnancy. 
 Out of the patients testing positive for anti-HPA alloantibodies, as expected, 
most of them were anti-HPA-1a reactive ones. The proportion of patients testing 
positive for the other anti-HPA antibodies is higher than what is found in prospective 
studies (see table 1). However, the numbers in our population is small, and it is not an 
unselected prospective one, but consists of patients with a clinical history where 
alloimmunization could be likely. To date, there is no screening programme, and the 
protocols for investigations of a thrombocytopenic newborn vary in different 
hospitals. In many cases the idea of alloimmunization as a cause will be dependent on 
the different doctors' experience. Also, moderate thrombocytopenia in an 
asymptomatic newborn may not be detected, or be attributed to other causes without 
referring for detection of antibodies. This last theory is supported by the fact that 
platelet counts in the referrals are mostly very low (average <30 x 109/L), however 
one might also think that the doctor writing the referral would rather write down the 
extremely low platelet counts, and so the patients referred might in reality have a 
higher mean platelet count. On the other hand, the low platelet counts are in 
concurrence with the fact that severe thrombocytopenia in an otherwise healthy term 
newborn is most often caused by FNAIT. 
 In eleven cases with a thrombocytopenic newborn, there were HPA antigen 
incompatibilities between mother and father but no anti-HPA antibodies detected. In 
two cases there were HPA-incompatibilities and anti-HLA antibodies detected, and in 
the further analysis of the specificities in these two cases the MFI values were low 
compared to the others, suggesting that the initial anti-HLA antibodies could be a 
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random finding. It is a possibility that the anti-HPA alloantibodies are not always 
detected. This could probably be due to the sensitivity of the assays and timing of the 
testing. Antibodies adsorbed on the platelets and other tissue will not be detected, and 
one could think that they can have been transferred from the mother earlier in the 
pregnancy. In such cases both repeated testing of the maternal sera and determining of 
her child's genotype could be useful to eventually confirm or disprove a FNAIT 
diagnosis.  
 Many of the children referred had other factors involved (infections, 
abnormalities, asphyxia); supporting the fact that thrombocytopenia can be caused by 
many things in addition to alloimmunization. The ones testing positive for anti-HLA 
class I alloantibodies were therefore divided into groups based on the presence of 
these other factors. However, for example in the cases with prematurity, one could 
speculate whether the anti-HLA alloimmunization could also be a contributing cause 
and an indication of maternal foetal rejection as suggested by Lee et. al (2011)[110], 
and not just a concomitant finding.  
 In the group of patients positive for anti-HLA class I antibodies alone ("Cases 
of possible alloimmunization"), 3/23 (13%) patients (excluding the HPA-1a negative 
mothers) delivered children who were small for gestational age (SGA) or had a low 
birth weight (<2500g). SGA is usually defined as newborns with a birth weight lower 
than the 10th percentile, so in an unselected population one could expect less than 
10% to be SGA. In our population of 260 referred patients, 12 (4.6%) of the children 
were said to be SGA. Four of these (33.3%) from mothers with alloantibodies 
detected, of which all were anti-HLA class I antibodies. The incidence of SGA is 
within what is expected range. The majority (66%) of mothers with thrombocytopenic 
SGA children did not have antibodies, however the proportion of anti-HLA class I 
antibody positive is still high. All the SGA children of antibody positive mothers also 
had other factors noted, like apnoe, hypoglycemia and hyperbilirubinemia. It is known 
that neonates born premature or with low birth weight are more often 
thrombocytopenic, but the reasons for this remain unknown. One could think that 
these neonates are for various reasons more prone to a number of different conditions 
that in turn can lead to thrombocytopenia. The association between thrombocytopenic 
SGA children and maternal anti-HLA class I antibodies was suggested by Koyama et 
al. (1991)[19]: In this report, 10/11 mothers of thrombocytopenic SGA children had 
antibodies, while 9/10 mothers of non-thrombocytopenic SGA children tested 
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negative. The number of cases is small, but the association seems strong and should 
be investigated further, to see if the presence of these maternal antibodies could cause 
or contribute to a thrombocytopenic SGA neonate.  
 The referred mothers with ITP all delivered healthy, non-thrombocytopenic 
children. Significant neonatal thrombocytopenia occurs in only 10% of cases with ITP 
during pregnancy (Bussel, 1997 [111]), and so this was as expected.  
 Suspected newly discovered intracranial haemorrhage was a reason for referral 
in 13/260 (5%) cases. The majority (59%) did not have antibodies, and those who did, 
had anti-HLA class I antibodies (6 patients, 35%) and autoreactive antibodies (1 
patient, 5.9%). The incidence of ICH caused by FNAIT is about 1:12500 in an 
unselected population, and so it is not unexpected that there were no cases of HPA 
immunization with ICH in a population of 260 referred patients. The platelet count 
was not known in these cases, and so it remains uncertain whether these really were 
cases of suspected alloimmunization. 
 The interpretation of the patients' clinical history is based on referrals only, 
which at best is a summary of the patient's history up until the time of referral, but in 
many cases the clinical information given is too limited. Even though the patients 
were firstly sorted and described based on laboratory findings, several are likely to be 
interpreted differently if more clinical information was available. On the other hand, 
the assessment of the patients by the referring doctors should also be trusted when 
considering which cases of neonatal thrombocytopenia are more or less likely to be 
caused by alloimmunization. 
Distribution	  of	  anti-­‐HLA	  class	  I	  antibody	  specificities	  
Most patients tested positive for a number of different specificities, with the average 
number of (high) positive specificities per patient at 14.9, and a wide range of 0 to 41.  
This could implicate that the antibodies were not specific against the different alleles, 
and/or that the mothers produced antibodies of very broad specificity.  
 In one investigation (Panzer et. al, 2005[112]) of anti-HLA class I antibodies 
in cases of suspected FNAIT, MAIPA and lymphocytotoxicity test (LCT) were used 
for detection of anti-HPA and anti-HLA antibodies: 3/17 sera were multispecific, 3 
had two specificities and six were single specificity, while six were negative with 
LCT. The LCT-specificities found were A2, A9, A28, B13, B5, B35. A light chain 
phenotype or restriction was not associated with any anti-HLA antibody pattern, and 
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the authors concluded that light chain restriction, indicating a clonal origin of 
antibodies reactive with a specific antigen, could not be used to determine which 
cases of HLA alloimmunization caused FNAIT. Although using a different test, this 
study indicates that finding antibodies of broad specificity is not surprising, and 
B*13:01 and B*13:02 were also of the most common specificities among our selected 
patients.  
 When the antibodies in the Luminex single antigen assay seem to be of so 
many specificities, the question is whether this is true, or if it represents cross 
reactivity: Atleast in three samples (Patient 8, 10 and 18), this seem to be the case, as 
a few specificities have a high MFI value, together with groups of specificities with 
lower MFIs. Then another question arises, as to how cross-reacting antibodies can 
influence and bind to foetal platelets. 
 Aside from the ones with a cross-reactivity-like pattern, many of the patients 
tested positive for several specificities using the high MFI-value cut-off.  Assuming 
this represents antibodies of broad specificities, the question is what the mechanism 
behind this could be.   
 Epitope spreading would generate antibodies of broader specificities, and can 
complicate and lead to autoimmune diseases, as reviewed by Vanderlugt and Miller 
(2002)[113]. The suggestion that anti-HLA class I antibodies is associated with 
chronic chorioamnionitis (Lee et al. 2011)[110], could perhaps lead to the idea that a 
similar mechanism is possible during pregnancy. 
 The most common antibodies were against presumably rare alleles, although 
data on the frequency of HLA-alleles in an unselected Swedish population were 
unavailable. HLA-B is more polymorphic than HLA-A, and so more specificities of 
HLA-B isotype were tested against and found. One could think that with rare 
antigens, these could be more immunogenic and the risk of alloimmunization higher. 
For instance, HLA A2 is common, and so this antigen is more likely to be introduced 
to the immune system during the course of life, and result in the creating of HLA-A2 
specific antibodies. However, in our population, HLA A2 is not among the most 
common antibody specificities using the high cut-off. If this is because a series of 
exposure to this antigen would eventually lead to tolerance, a lower concentration of 
HLA-A2 specific antibodies, or to a broad spectrum of cross reacting ones, is unclear. 
 The anti-HLA class I antibodies detected may also represent naturally 
occurring antibodies. In a study describing anti-HLA class I antibodies (Zhou et. al 
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2008[114]) found in SLE patients and normal controls with and without a history of 
pregnancy, 2/10 female controls without a history of pregnancy had antibodies (4/10 
with a history). 16/130 healthy male controls also had antibodies. 10/16 had against 1-
2 antigens, and the rest against 3-31 antigens. None of these antibodies corresponded 
to the individuals' own HLA antigens, they did not cross react, and eight of the 32 
antigens tested were rare antigens in the Japanese population. The authors suggested 
the antibodies could be generated through an immune response against environmental 
agents, such as bacteria and viruses. Other possible mechanisms suggested were 
foetal-maternal immunisation (however, the subject examined had 3/4 antibodies not 
corresponding with the mother's antigens), antibody-response through sexual contact 
(which does not explain the occurrence of the rare antibodies) and autoantibodies 
normally found in individuals, reactive with a variety of proteins and cell surface 
structures (but the antibodies detected did not correspond to the individual's own HLA 
antigens). Individuals testing positive for a variety of antibodies, of which several are 
rare ones, is similar to that found in this report, but the patients in our population were 
not genotyped for their HLA antigens and so it is hard to draw any conclusions, 
although it remains a possibility that naturally occurring anti-HLA antibodies could 
have been detected. Our selected patients had given birth to thrombocytopenic 
children. Naturally occurring anti-HLA class I antibodies could in theory be 
transported across the placenta, as they are IgG, but this has not been described. 
 To answer some of these questions mentioned above, a control population 
would be useful to see how the distribution of anti-HLA class I antibody specificities 
look in a normal antenatal or postnatal population of mothers. The sub-analysis of the 
data on the specificities is also unsatisfactory, and proper cut-off should have been 
made to better differentiate the MFI-values. The antibodies could also be grouped 
after public and private epitopes, or cross reactive groups (CREGs), but this is a 
challenge, as the different specificities can belong to more than one group.  
 Regarding the selection of patients where the anti-HLA class I antibodies were 
further investigated, this was based on the clinical information in the referrals, and 
could have been different if a more complete history was available. The lack of 
negative findings in the referrals probably led to an overestimation of cases of 
possible anti-HLA alloimmunization. Taking into consideration the rarity of FNAIT, 
and subsequently the assumed rarity of HLA-caused FNAIT, the number of cases is 
likely too high. Including too many in the analysis of the anti-HLA antibody 
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specificities would have made a conclusive result more difficult to obtain when trying 
to single out specificities more prone to cause neonatal thrombocytopenia.  
 To properly set the diagnosis of FNAIT caused by HLA alloimmunization, a 
genotyping of mother and father should be performed, similar to what is done when 
diagnosing FNAIT caused by platelet specific antigens. 
Expression	  of	  HLA	  class	  I	  on	  platelets	  in	  adult	  and	  umbilical	  cord	  blood	  
In the flow cytometry investigations, T-cells showed the highest expression of HLA-
A and HLA-B/HLA-BC, and platelets the lowest. T-cells also had the widest range of 
MFI-FMO values in both adults and cord blood. The high expression is not surprising 
when considering the functional role of T-cells. The high variation could be a result of 
both genetic (different combinations of genes could translate into different levels of 
expression) and environmental factors (like the presence of infectious agents).  
 Comparing the mean MFI-FMO values directly, platelets had 11% of T-cell 
HLA-ABC and about 5% of T-cell HLA-BC in both adults and cord blood. The 
density of HLA antigens on the surface might be lower on platelets, but because they 
are in abundance in blood (trc 150-400 x109/L vs. white blood cell count 4.5-
10x103/L), they still constitute the major part of HLA in blood and can then be more 
likely to bind antibodies.   
 Since the size of the cells influences the forward scatter (FSC), this could 
affect the MFI-values, which could contribute to the seemingly reduced HLA 
expression on platelets. It would also explain some of the variation of HLA 
expression, since the platelet size varies between individuals because of genetic 
factors [115]. This was not adjusted for in our analysis, however the FSC did not 
seem to correlate with MFI-values. 
 The neutrophils are the largest cells and so have more auto fluorescence. They 
also show the largest difference in HLA-ABC and HLA-BC when comparing adult 
and cord blood, the cord blood values were almost twice as high for HLA-ABC and 
50% of adult HLA-BC. Why the difference seems to be so great in neutrophils is not 
clear.  
 In our analysis, all the umbilical cord blood cells had a higher mean HLA-
ABC MFI-FMO than the adult cells, and the difference seemed to be greatest in 
platelets. The lower HLA-A values in adult blood compared to cord blood is in 
concurrence with the report by Le Morvan et al. (1998)[116], who investigated HLA-
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ABC, HLA-A, HLA-B and HLA-DR in peripheral blood from 58 healthy subjects 
aged 23-95 years old. The authors observed a significant decrease in the expression of 
HLA class I on T-cells with increasing age, which concerned only HLA-A products. 
In a more recent report (Le Morvan et al., 2001 [117]), both HLA-A and HLA-B 
mRNA and transcripts were shown to decrease with increasing age, but affecting 
HLA-A antigens to a greater extent than HLA-B.   
 Another report by Higuchi et al. (2003)[76] used flow cytometry and ELISA 
to compare membrane bound HLA class I and DR from mononuclear cells (MNCs) 
and soluble HLA levels in adult peripheral blood (PB) and umbilical cord blood. The 
MFI for membrane bound HLA class I on MNCs and soluble HLA was found to be 
lower in cord blood compared to adult, but because of higher cell numbers in cord 
blood, the total concentrations of membrane bound HLA per ml blood were 
equivalent. sHLA class I concentrations were significantly lower in cord blood. As we 
in our report used two different antibodies for HLA class I (HLA-ABC and HLA-
BC), which seemed to show different expression in adult and cord blood cells, it is 
difficult to compare results of total HLA class I expression directly. In addition, we 
also analysed the expression on different cells, using platelets, T-cells and neutrophils, 
and not only MNCs. During the analysis, we used a cell number of about 10,000 per 
cell type and then calculated mean MFI values. We did not compare these values with 
the cell concentration in the different samples. 
 In this assay it was assumed that the MFI values for HLA-BC would 
correspond to the expression of HLA B, because of a presumably consistent low 
expression of HLA-C on platelets. The evidence for this in the available literature is 
not conclusive, and variation of HLA-C expression may contribute to the variation of 
HLA-BC MFI values.  
 When the results from these two investigations are taken together with 
available literature, it is obvious that a number of questions are still unanswered: For 
instance, could a combination of a foetus with higher HLA class I expression on 
platelets and a mother with common, pregnancy-induced broad reacting HLA I 
antibodies lead to thrombocytopenia in the newborn? Analysis of HLA expression 
levels on platelets of affected foetuses could then prove useful. More likely, specific 
differences in HLA genotypes are necessary to induce an appropriate immune 
response, leading to a higher concentration of maternal antibodies. But if so, it is 
surprising that the antibodies in these cases also seem to be of broad reactivity. Since 
	   44	  
the platelet expression of cord blood HLA-B is lower, the high numbers of HLA-B 
reacting antibodies could be explained by increased HLA-B polymorphism, 
suggesting that rare alleles are more immunogenic. When considering these aspects, 
one should have a suitable control group with anti-HLA class I antibody positive 
mothers that have undergone a normal pregnancy with a healthy neonate. Since anti-
HLA class I antibodies would have more binding sites other than platelets, one could 
think that the presence of these antibodies in maternal circulation could lead to other 
effects in the foetus. And perhaps would such effects be dependent on antibody 
concentration, with platelet HLA acting as a "buffer". In this respect, umbilical cord 
blood from both healthy and thrombocytopenic neonates could be tested for maternal 
anti-HLA class I antibodies. 
Conclusion	  
In this report, 260 patients referred to the thrombocyte and leukocyte laboratory for 
detection of thrombocyte antibodies in cases of suspected FNAIT were presented. 
43% had detectable antibodies. FNAIT caused by HPA incompatibility with 
detectable anti-HPA antibodies was diagnosed in 35 out of 260 referred patients. The 
most common antibody finding was anti-HLA class I antibodies. In selected cases of 
suspected HLA alloimmunization, most of the patients had anti-HLA class I 
antibodies reacting with a high number of allele specific antigens, and the majority 
was HLA-B antibodies reactive with rare HLA-B alleles. We found an increased 
expression of HLA-A and decreased expression of HLA-BC on umbilical cord blood 
platelets compared to adult peripheral blood platelets. 
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Figure	  20	  Histogram	  of	  number	  of	  patients	  
testing	  positive	  per	  anti-­‐HLA	  class	  I	  antibody	  
specificity.	  	  The	  blue	  bars	  denote	  the	  number	  of	  
patients	  testing	  positive	  with	  high	  (MFI	  >/=	  
15,000)	  cut-­‐off,	  and	  the	  red	  bars	  the	  number	  of	  
patients	  testing	  positive	  with	  the	  medium	  
(MFI>10,000-­‐14,999)	  cut-­‐off.	  All	  allele	  specific	  
antibodies	  tested	  for	  are	  included.	  
